HEALTH OF WOMAN. 2016.5(111):101–108; doi 10.15574/HW.2016.111.101 
 

Modern approaches to the treatment of mastitis in women of reproductive age 
 

Sukhanova A. A., Melnik Yu. M., Karlova O. O.

Shupyk National Medical Academy of Postgraduate Education, Kiev, Ukraine

Kiev city center of reproductive and perinatal medicine

A.A. Bogomolets National Medical University, Kiev 
 

The aim of the study: to study the efficacy and safety of use Mastofemin in the treatment of various forms of mastitis in women of reproductive age.

Materials and methods. The study included 62 women of reproductive age (mean age of 33.5±2.3 years) who were screened in the Kiev city center reproductive and perinatal medicine. Women were divided into 2 groups. The first (main) group consisted of 32 patients who received the proposed treatment using herbal remedies Mastofemin 1 capsule 2 times per day for 3 months; 30 patients of the second (control) group were under observation and received no treatment. These groups were representative and homogeneous on age, clinical symptoms and sonographic characteristics. The clinical method included evaluation of complaints of patients, anamnesis, presence of concomitant gynecologic pathology, inspection, palpation of the lymph nodes and the breast and obtaining a discharge from the nipples to conduct cytological examination, which allowed excluding from the study women with suspected malignancy of the process. All the patients were performed ultrasound examination of the breast. The review was supplemented with vaginal gynecological examination and ultrasound examination of small pelvis organs to assess the condition of the uterus and its appendages, the diagnosis of gynecological diseases.

Results. Summarizing obtained in this study results one should stress the positive long-term effect of applying Mastofemin for the treatment of proliferative changes of the breast in women of reproductive age. This is manifested by a decrease in the intensity of clinical signs of mastitis, consistent with the results of sonographic control. Established positive dynamics in the treatment of cystic mastitis, dectective and when combined cystic mastopathy with dectective.

In the control group of patients for a given observation period (6 months) no significant changes in clinical signs of mastitis and sonographic characteristics. Regression of disease has not occurred in any of the patients, in 2 patients increased sensitivity of the breast after 6 months moved to the soreness. Sonographic characteristics of mastitis during the observation period did not change. Thus, the use of Mastofemin aimed at pathogenetic treatment of mastitis and prevention of breast cancer.

Conclusion. Application of Mastofemin during the treatment of mastitis in women of reproductive age significantly improves the clinical condition of patients; reduce the subjective and objective symptoms of the disease. The positive effect of the treatment with Mastofemin proved in the case of the treatment of sonographic following forms of mastitis: cystic mastopathy, cystic mastopathy with dectectasy. Mastofemin may be the drug of choice for complex conservative monotherapy in women of reproductive age with proliferative changes in the breast, and can also be used as part of complex treatment in patients with diffuse changes of the breast when combined with hyperplastic processes of the myometrium and endometrium.

Keywords: mastopathy, breast gland, herbal medicine, herbal remedies, Mastofemin.

REFERENCES

1. Aceves С, Anguiano В, Delgado G. 2005. Is iodine a gatekeeper of the integrity of the mammary gland? J. Mammary Gland Biol. Neoplasia. 10:189–196. http://dx.doi.org/10.1007/s10911-005-5401-5; PMid:16025225

2. Ahn WS, Yoo J, Huh SW, Kim CK, Lee JM, Namkoong SE, Bae SM, Lee IP. 2003, Oct. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions. Eur J CancerPrev. 12(5):383–90. http://dx.doi.org/10.1097/00008469-200310000-00007; PMid:14512803

3. Huber J. 2000. Phytoestrogens and SERMS, alternatives to classical hormone therapy10Ther. Umsch. 57:651–654 (German). http://dx.doi.org/10.1024/0040-5930.57.10.651; PMid:11081378

4. Hudson EA, Howells L, Ball HW, Pfeifer AM, and Manson MM. 1998. Mechanisms of action of indole-3-carbinol as a chemopreventive agent. Biochem.Soc.Trans. 26(4):S370. http://dx.doi.org/10.1042/bst026s370; PMid:10047884

5. Joanne Barnes, Linda Anderson A, David Phillipson J. 2007. Herbal Medicines, 3rd Edition. Pharmaceutical Press, London:498–499, ISBN 978 0 85369 623 0

6. Matsuzaki Y, Koyama M, Hitomi T, Kawanaka M, and Sakai T. 10-8-2004. Indole-3-carbinol activates the cyclin-dependent kinase inhibitor p15 (INK4b) gene. FEBS Lett. 576(1-2):137–140. http://dx.doi.org/10.1016/j.febslet.2004.09.002; PMid:15474025

7. Meng Q, Qi M, Chen D-Z, Yuan R, Goldberg ID, Rosen EM, Auborn K & Fan S. 2000. Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J. Mol. Med. 78:155–165. http://dx.doi.org/10.1007/s001090000088; PMid:10868478

8. Meng Q, Yuan F, Goldberg ID, Rosen EM, Auborn K & Fan S. 2000. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J. Nutr. 130:2927–2931. Miltenburg OM, Speights VO. 2008. Benign breast disease. Obstet. Gynecol. Clin. North Am. 35:285–300.

9. Rahman KM, Li Y, and Sarkar FH. 2004. Inactivation of akt and NF-kappaB play important roles during indole-3-carbinol-induced apoptosis in breast cancer cells. Nutr.Cancer 48(1):84–94. http://dx.doi.org/10.1207/s15327914nc4801_12; PMid:15203382

10. Spinos N, Terzis G, Crysanthopoulou A el at. 2007. Increased frequency of thyroid nodules and breast fibroadenomas in women with uterine fibroids. Thyroid. 17:1257–1259. http://dx.doi.org/10.1089/thy.2006.0330; PMid:17988198

11. Wang HK. 2000. The therapeutic potential of flavonoids. Expert Opin. Investig. Drugs 9:2103–2119. http://dx.doi.org/10.1517/13543784.9.9.2103; PMid:11060796

12. Andreeva EN, Ledneva EV. 2002. Osnovnyie aspektyi etiologii i patogeneza fibrozno-kistoznoy bolezni molochnoy zhelezyi. Akusherstvo i ginekologiya:6.

13. Zotov AS, Belik EO. 2005. Mastopatii i rak molochnoy zhelezyi. M, MEDpress-inform:112.

14. Kolz A. 2002. Rak molochnoy zhelezyi: zabolevaemost rastet, vyibor lecheniya ogranichen. Tochka zreniya 19;4:1–8.

15. Letyagin VP. 2000. Mastopatiya. Ginekologiya 11:468–472.

16. Likarski roslyny: Entsyklopedychnyi dovidnyk. Vidp. red. AM Hrodzinskyi. K, Vydavnytstvo «Ukrainska Entsyklopediia» im. M.P. Bazhana, Ukrainskyi vyrobnycho-komertsiinyi tsentr «Olimp». 1992:544.

17. Mamchur FI. 1984. Dovidnyk z fitoterapii. K, Zdorov’ia:246–247.

18. Manusharova RA, Cherkezova EI. 2004. Fibrozno-kistoznaya mastopatiya: klinika, diagnostika i lechenie. Lechaschiy vrach:10.

19. Muraveva DA, Samyilina IA, Yakovlev GP. 2002. Farmakognoziya: Uchebnik. – 4e izd., pererab. i dop. M, Meditsina:656. (Ucheb. lit. dlya stud. farm. vuzov).

20. Ozerova OE. 2001. Normalnyie ehograficheskie osobennosti strukturyi molochnyih zhelez v razlichnyie vozrastnyie periodyi, pri beremennosti i laktatsii. Sonoaceinternational. Vyip. 9:50–57.

21. Radzinskiy VE, Ordiyants IM, Zubkin VI i dr. 2006. Nerakovyie zabolevaniya molochnyih zhelez i ginekologicheskie zabolevaniya. Zhurnal Rossiyskogo obschestva akusherov-ginekologov 2:34–42.

22. Tagieva TT. 2005. Fibrozno-kistoznaya mastopatiya. Ginekologiya 7:3.

23. Chayka VK, Lasachka SA, Gukova DYu, Umanskaya ES. 2013. Diagnostika, lechenie i profilaktika zabolevaniy molochnyih zhelez v usloviyah reformirovaniya sistemyi zdravoohraneniya v Ukraine. Meditsinskie aspektyi zdorovya zhenschinyi 1(64):5–9.

24. Chistyakov SS. 2006. Fibrozno-kistoznaya bolezn i dobrokachestvennyie opuholi molochnyih zhelez. Klinicheskaya mammologiya. Sovremennoe sostoyanie problemyi. Pod red. EB Kampovoy-Polevoy, SS Chistyakova. M, GEOTAR-Media:116–143.